Neurological Focus Opportunity to position partnerships around neurological diagnostics given Fujirebio’s strength in biomarkers and recent expansion of the Lumipulse platform with NfL and pTau tests, aligning with demand for blood-based Alzheimer's and neurodegenerative screening.

Strategic Partnerships Leverage Fujirebio’s open model and CDMO capabilities to propose joint development and manufacturing collaborations, especially for high-demand IVD content and real-world validation through Lumipulse and SRL networks.

Clinical Collaboration Target collaborations with academic centers and hospitals through the Stanford Medicine alliance to co-develop infectious disease diagnostics and leverage their global lab networks for validation and deployment.

Global Expansion Capitalize on recent acquisitions and regional reach by offering integrated supply of raw materials and diagnostic components via Plasma Services Group and related materials, expanding into new geographies and platforms.

Regulatory Momentum Highlight CE marking and FDA-cleared Lumipulse tests as credibility signals to accelerates co-development and market entry strategies with diagnostics companies seeking compliant, globally deployable solutions.